All In Biotech

Drug Trial Radar · NCT02405260

Add Glucokinase Activator to Target A1c

A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin

Last checked: Nov 19, 2026Latest source record: Feb 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Mar 2015

Primary completion

Jul 2016

Study completion Sep 2016

Sponsor

Lead sponsor
vTv TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • TTP399 400 mgDrug

    once daily

  • TTP399 800 mgDrug

    once daily

  • Sitagliptin 100 mgDrug

    once daily

  • PlaceboDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c (Glycosylated haemoglobin)Time frame: Day 1 to Day 168

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Mesa, Arizona

  • Site not named

    Tuscon, Arizona

  • Site not named

    Canoga Park, California

  • Site not named

    Huntington Park, California

  • Site not named

    Los Angeles, California

  • Site not named

    West Hills, California

  • Site not named

    Centennial, Colorado

  • Site not named

    Littleton, Colorado

  • Site not named

    Waterbury, Connecticut

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Gurnee, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    Rochester, Minnesota

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Moncks Corner, South Carolina

  • Site not named

    San Antonio, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Schertz, Texas

  • Site not named

    Norfolk, Virginia

  • Site not named

    Richland, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.